Key Takeaways
- • A consortium of three major private equity firms—Blackstone Group, Carlyle Group, and Hellman & Friedman LLC—acquired Medline Industries in a $34 billion leveraged buyout, defeating a rival bid from Brookfield Asset Management.
- • Medline, a Northfield, Illinois-based medical supply and equipment distributor with $17.5 billion in 2020 revenue and 28,000 employees globally, will remain privately held with the founding Mills family retaining the largest single shareholder position.
- • The transaction structure involved approximately $17 billion in equity—including a rollover stake by the Mills family—with the remainder financed through debt, marking one of the largest leveraged buyouts since the 2008 financial crisis.
- • Medline's senior management team and CEO Charlie Mills will remain in place; the company plans to deploy the new capital for international expansion and global supply chain strengthening.
- • The deal represents significant institutional capital deployment in healthcare infrastructure, with the acquiring consortium gaining control of a diversified medical product portfolio spanning hospital supplies, anesthesia, mobility equipment, and consumer brands like Curad across more than 110 countries.
Summary
A consortium comprising Blackstone Group, Carlyle Group, and Hellman & Friedman LLC closed a $34 billion leveraged buyout of Medline Industries, one of the largest private equity transactions since the 2008 financial crisis. The deal, announced in early June 2021, surpassed a competing offer from Canadian asset manager Brookfield Asset Management. The three-firm partnership secured a controlling stake in the family-run company while preserving ownership continuity for the Mills family, who retain the largest single shareholder position.
Medline, headquartered in Northfield, Illinois, operates as a global leader in medical supply distribution and manufacturing. The company generated $17.5 billion in revenue during 2020 and maintains a workforce of 28,000 employees across operations in more than 110 countries. Its product portfolio encompasses a broad range of healthcare inputs, from anesthesia and surgical supplies to mobility equipment such as wheelchairs and beds, alongside consumer healthcare products including the Curad brand. The company serves hospitals, healthcare centers, and institutional buyers worldwide.
The transaction's financing structure reflected disciplined capital allocation, with approximately $17 billion comprising equity capital—including the Mills family's rollover investment—and the remainder financed through debt instruments. This equity-heavy composition reduced execution risk relative to traditional highly leveraged buyout structures. Management continuity was preserved entirely; Charlie Mills remained as chief executive officer, and the complete senior management team stayed in place, signaling confidence in operational leadership and strategic direction.
The acquiring consortium indicated capital deployment focused on two primary strategic initiatives: accelerating international expansion and strengthening Medline's global supply chain infrastructure. These objectives align with the company's existing geographic footprint and market positioning as a diversified healthcare supplier. By maintaining private ownership and providing growth capital without operational disruption, the deal positioned Medline to capitalize on expanding demand for medical equipment and supplies across developed and emerging healthcare markets.
Medline, headquartered in Northfield, Illinois, operates as a global leader in medical supply distribution and manufacturing. The company generated $17.5 billion in revenue during 2020 and maintains a workforce of 28,000 employees across operations in more than 110 countries. Its product portfolio encompasses a broad range of healthcare inputs, from anesthesia and surgical supplies to mobility equipment such as wheelchairs and beds, alongside consumer healthcare products including the Curad brand. The company serves hospitals, healthcare centers, and institutional buyers worldwide.
The transaction's financing structure reflected disciplined capital allocation, with approximately $17 billion comprising equity capital—including the Mills family's rollover investment—and the remainder financed through debt instruments. This equity-heavy composition reduced execution risk relative to traditional highly leveraged buyout structures. Management continuity was preserved entirely; Charlie Mills remained as chief executive officer, and the complete senior management team stayed in place, signaling confidence in operational leadership and strategic direction.
The acquiring consortium indicated capital deployment focused on two primary strategic initiatives: accelerating international expansion and strengthening Medline's global supply chain infrastructure. These objectives align with the company's existing geographic footprint and market positioning as a diversified healthcare supplier. By maintaining private ownership and providing growth capital without operational disruption, the deal positioned Medline to capitalize on expanding demand for medical equipment and supplies across developed and emerging healthcare markets.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.